Infectious agent offers protection against liver cancer

- EN - DE
Inga Hochnadel (left), Tetyana Yevsa (centre), Lisa Hönicke (right) in the labor
Inga Hochnadel (left), Tetyana Yevsa (centre), Lisa Hönicke (right) in the laboratory; Copyright: Karin Kaiser/ MHH.

Joint study by MHH and HZI: vaccine proves safe and effective against liver fibrosis and liver cancer

Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been inadequate, while the number of new cases has been rising. A study by researchers at the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) now offers hope. A vaccine based on a highly attenuated infectious agent called Listeria monocytogenes proved to be safe and effective protection in premalignant and malignant liver diseases in preclinical mouse models. ...

account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.